However, we recommended evaluating for TPO receptor (MPL), particularly in hepatocellular carcinoma, when available, to confirm the absence of MPL mRNA or protein expression before commencing TPO-RA usage [126,127]. Here, MPL is linked to hepatocellular carcinoma.